Bonanza Creek Energy Announces Fourth Quarter and Full Year 2017 Financial and Operating Results
Mar 14, 2018 21:00 pm UTC| Business
Quarterly GAAP cash flow from operating activities of $16.2 million; adjusted EBITDAX(1) of $21.6 million; GAAP net loss of $0.28 per diluted share; adjusted net income(1) of $0.40 per diluted share2017 all-in finding and...
Bancorp of New Jersey Reports 2017 Fourth Quarter and Full Year Financial Results
Mar 14, 2018 21:00 pm UTC| Business
FORT LEE, N.J., March 14, 2018 -- Bancorp of New Jersey, Inc. (NYSE American:BKJ) (the “Company”), holding company for Bank of New Jersey (the “Bank”), today reported financial results for its fourth quarter and full...
NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
Mar 14, 2018 21:00 pm UTC| Business
AMES, Iowa, March 14, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Association for Cancer...
Mar 14, 2018 20:59 pm UTC| Business
CAMBRIDGE, Mass., March 14, 2018 -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating...
Impac Mortgage Holdings, Inc. Announces Year End 2017 Results and Management Changes
Mar 14, 2018 20:56 pm UTC| Business
IRVINE, Calif., March 14, 2018 -- Impac Mortgage Holdings, Inc. (NYSE American:IMH) announces the financial results for the quarter and year ended December 31, 2017. 2017 Financial Results For the year ended...
Finjan Delivers Strong Fiscal Year 2017 Results
Mar 14, 2018 20:54 pm UTC| Business
EAST PALO ALTO, Calif., March 14, 2018 -- Finjan Holdings, Inc. (NASDAQ:FNJN), a cybersecurity company, is providing shareholders with its audited financials for the fiscal year ended December 31, 2017. Additional...
Mar 14, 2018 20:50 pm UTC| Business
WALTHAM, Mass., March 14, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data for ZEJULA, TSR-042 (anti-PD-1 antibody) and the company’s immuno-oncology portfolio...